- OptiScan establishes new North America Distributor Arrangements
- Plans to establish new Asia Pacific Distribution Arrangements
OptiScan Imaging Limited (ASX: OIL) (‘the Company’ or ‘OptiScan’) is pleased to advise that it has altered its North American distribution arrangements. It has entered into an agreement with Advanced Microscopy Consultancy Services Inc (‘AMCS’) to provide technical, marketing and sales services to the Company in the United States and Canada. AMCS possesses significant pre-clinical microscopy and imaging expertise as well as multiple contacts in the research community.
The Company also advises that it has ended the Distribution Agreement with Scintica Instrumentation Inc (‘Scintica’) although it continues to explore potential opportunities to work with Scintica.
These changes to the Company’s marketing and distribution activities in North America follow the Company’s recent engagement of Dr Joseph Jiafu as a consultant to assist the Company to establish distribution arrangements in Japan, Korea, Singapore and other APAC countries (excluding China). Dr Jiafu is a microscopy expert and the former Asia Pacific In Vivo product leader for PerkinElmer Inc.
Executive Chair and CEO of OptiScan, Darren Lurie, said “We are excited to build upon our recent sales in the China market by adding highly qualified and experienced people to develop sales and distribution opportunities in North America and Asia. In addition, we have been able to enhance the technical, microscopy and pre-clinical application knowledge within the Company which will benefit us in all markets.”
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.